Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
October 05, 2015 01:00 AM

Trade deal disappoints drugmakers, consumer groups

Lisa Schencker
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Getty Images
    President Barack Obama meets with leaders from the Trans-Pacific Partnership at the U.S. embassy in Beijing in November 2014.

    A trade agreement between the U.S. and 11 other countries has left both the drug industry and consumer groups disappointed over intellectual protections of certain drugs.

    The deal, known as the Trans-Pacific Partnership Agreement, may also face congressional scrutiny, some say.

    Part of the agreement requires the countries to extend data protection for biologic medicines—drugs produced by living matter—for at least five to eight years. The pharmaceutical industry had hoped for a minimum of 12 years, and some consumer groups had hoped for no minimum exclusivity.

    Such exclusivity prevents, for a certain length of time, competing drug companies from bringing biosimilars, which are drugs very similar to an existing biologic, to market based on clinical trial data from the original drug.

    Biologics currently have 12 years of data exclusivity in the U.S. under federal law, and that's unlikely to change regardless of the trade agreement. The biggest impact will be felt by some of the partnership's other countries; Australia, Brunei, Vietnam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru and Singapore.

    Some countries don't currently have any exclusivity for biologics, meaning the agreement would require them to pass laws granting at least five years of exclusivity.

    “In the U.S., I don't think there would be that much that would need to change,” said Joy Liu, a partner at Ropes and Gray who advises drug and biotech companies on FDA-related matters.

    Liu said biosimilar competition on foreign markets could impact companies, some of which are based in the U.S., because they've invested in the R&D.

    The industry agreed.

    “PhRMA believes that strong intellectual property protection is necessary for the discovery and development of new treatments and therapies for the world's patients,” said John Castellani, CEO of industry group the Pharmaceutical Research and Manufacturers of America, in a statement. He called biologic medicines the “next wave of innovation in our industry.”

    “While we await final details, it appears that the Ministers missed the opportunity to encourage innovation that will lead to more important, life-saving medicines that would improve patients' lives,” Castellani said.

    But Peter Maybarduk, director of consumer advocacy group Public Citizen's Access to Medicines Program, said that while the deal fell short of the 12 years the industry had hoped for, it still delays biosimilars from entering the market for too long.

    “The problem of drug pricing is increasingly out of control in the U.S. and everywhere,” Maybarduk said. “Of course we need to pay for medical innovation, but there are more efficient ways to do that than monopolies.”

    Doctors Without Borders also criticized the deal.

    “Although the text has improved over the initial demands, the [trade agreement] will still go down in history as the worst trade agreement for access to medicines in developing countries, which will be forced to change their laws to incorporate abusive intellectual property protections for pharmaceutical companies,” said Judit Rius Sanjuan, legal policy adviser to the group's access campaign, in a statement.

    Maybarduk said he doesn't believe data exclusivity is needed given that biologics also carry patents.

    Patents keep biosimilars from entering the market for a period of time. But the pharmaceutical industry has argued that 12 years of exclusivity was also needed in the U.S. because patent laws in the areas of biotechnology are weaker than those for traditional drugs, said Arti Rai, a law professor at Duke University and expert in intellectual property law and health policy.

    Whether Congress will agree to the trade deal is still a matter of speculation. Before negotiations were complete, Congress agreed to fast track the agreement, meaning Congress must simply vote it up or down without amending it.

    Sen. Orrin Hatch (R-Utah), who chairs the Senate Finance Committee, has already said that for any trade agreement to win his approval it must strengthen the intellectual property right laws of the U.S.'s trade partners. He's said that he fully expected the Trans-Pacific Partnership agreement to include 12 years of regulatory data protection for biologics.

    Opposition could also come from the other side of the aisle. In July, 11 Democrats wrote a letter expressing concern that the agreement may fail to pass muster if it doesn't meet standards set under a previous agreement. That one, reached by House democrats and President George W. Bush in 2007, sought to address what future trade agreements should contain. That previous agreement set exclusivity at five years.

    “As members who support trade done right, we strongly believe that the [Trans-Pacific Partnership] must not inhibit access to lifesaving medicines,” the lawmakers wrote.

    Rai said the agreement's chances of passing through Congress will depend on a “complicated mix of politics.”

    “It's certainly a compromise, there's no doubt about that,” Rai said of the trade agreement. “In general, compromise in these areas seems to be better than one side entirely winning the game.”

    Janelle Waack, a partner at Bass Berry and Sims who works with pharmaceutical companies on patent and regulatory issues, said Congress will have to weigh the consequences of the agreement.

    “[Drugmakers] made a substantial investment both in terms of time and money to research and develop biologics and it can take 10 years or more to recoup the cost of that investment," Waack said.

    She advised that Congress carefully consider the impact on the pharmaceutical industry and smaller companies that are doing the ground level research, saying the agreement raises questions about whether they would continue "to pursue these lines of research in view of what could be a more limited period of exclusivity."

    "Are (they) going to pursue these lines of research in view of what could be a more limited period of exclusivity?” she wondered.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    cvs health_i.png
    Oak Street Health shares soar on report of CVS deal
    patient and money_i.png
    Headwinds didn't quell healthcare private equity deals in 2022
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing